Recognizing The Journal of Alzheimer’s Disease
By Dharma Singh Khalsa, MD, Medical Director
There are many medical journals that publish research. Typically, the highly prestigious journals publish the most solid and reputable research. At ARPF, we want to acknowledge the work of one such publication, the Journal of Alzheimer’s Disease (JAD).
Over the course of the last 22 years, JAD has published more papers on Alzheimer’s disease (AD) than any other journal. Furthermore, JAD has received more citations than any other AD-focused journal. JAD is now published semi-monthly, has a parallel book series, and has launched the open access JAD Reports, as well as sister journals on Parkinson’s, Huntington’s and Neuromuscular Diseases.
Most importantly from our point of view, JAD has shown remarkable openness and welcoming of integrative medicine or lifestyle-based papers. To name just a few, JAD was the first journal to feature articles on brain-health effects of walnuts, coffee, virgin olive oil, wine, meditation, yoga, and other lifestyle interventions.
Moreover, the Editorial Board of JAD decided to create a volunteer position of Prevention Editor since the last couple of years, which I have been honored to fill.
JAD’s Editor-in-Chief George Perry, PhD recalls the early days of the journal, “The plan was to design a journal that reflected the field through creating community. Editorial structure, openness to novel topics, reviewer selection, scientometric analysis, awards programs, and historical compendiums were all focused on building a JAD community. And JAD would not be JAD without the constant bantering of Mark A. Smith, PhD to push the envelope of what a journal could add to our field.“ (Mark was the co-Editor-in-Chief until his untimely passing in 2010.)
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease. JAD’s targeted audience is comprised of basic science researchers and clinicians in the areas of Alzheimer’s disease and related disorders.
We salute Dr. George Perry and the team at JAD for their dedication and openness to breakthrough research in Alzheimer’s disease.
For more information:
Find JAD on Facebook.
Follow JAD on Twitter.
Visit the JAD website.